Last ¥3,405 JPY
Change Today -55.00 / -1.59%
Volume 1.1M
As of 2:00 AM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

chugai pharmaceutical co ltd (4519) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/31/14 - ¥3,510
52 Week Low
10/8/13 - ¥1,910
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHUGAI PHARMACEUTICAL CO LTD (4519)

Related News

No related news articles were found.

chugai pharmaceutical co ltd (4519) Related Businessweek News

No Related Businessweek News Found

chugai pharmaceutical co ltd (4519) Details

Chugai Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in Japan and internationally. Its products in oncology include Avastin, Herceptin, Rituxan, Xeloda, Tarceva, Neutrogin, and Perjeta; bone and joint disease products comprise Actemra, Suvenyl, Edirol, Alfarol, and Bonviva; renal disease products consist of Mircera, Oxarol, and Epogin; and other products, such as Tamiflu, Sigmart, CellCept, Pegasys, and Copegus. The company has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, central nervous system, respiratory diseases, and other diseases. Chugai Pharmaceutical Co., Ltd. has a strategic alliance with Roche; and co-development agreement with Taisho Pharmaceutical Co., Ltd., as well as co-marketing agreement with Taisho Toyama Pharmaceutical Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

6,872 Employees
Last Reported Date: 03/27/14
Founded in 1925

chugai pharmaceutical co ltd (4519) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: ¥266.0M
President, Chief Operating Officer and Repres...
Total Annual Compensation: ¥74.0M
Compensation as of Fiscal Year 2013.

chugai pharmaceutical co ltd (4519) Key Developments

Chugai Pharmaceutical Co. Ltd. Announces Organizational Changes

Chugai Pharmaceutical Co. Ltd. announced that it will make organizational changes, effective October 1, 2014. To enhance compliance and corporate governance in medical activity, and establish new structure aligned to changing circumstances, Chugai will make organizational changes on Medical Affairs Div. as follows: Change the name of Medical Affairs Div. (Only in Japanese name); Change the names of 'Medical Education & Training Dept.' and 'Product Research Dept.' respectively (Only in Japanese name); Establish 'Medical Planning Dept.' in Medical Affairs Div.; Establish 'MSL: Medical Science Liaison Section' in Medical Plan Management Dept. and transfer some functions to MSL Section from Medical Coordination Section, which is placed at each branch.

Chugai Pharmaceutical Co. Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2014; Announces Dividend for the Second Quarter of 2014, Payable on September 1, 2014; Provides Dividend Guidance for the Year End of Fiscal 2014; Provides Consolidated Earnings Guidance for the Year Ending December 31, 2014

Chugai Pharmaceutical Co. Ltd. reported unaudited consolidated earnings results for the six months ended June 30, 2014. For the period, the company's revenues were JPY 222,022 million compared to JPY 201,016 million a year ago. Operating profit was JPY 43,117 million compared to JPY 38,120 million a year ago. Profit before taxes was JPY 43,435 million compared to JPY 36,946 million a year ago. Net income was JPY 29,425 million compared to JPY 25,261 million a year ago. Net income attributable to the company shareholders was JPY 28,897 million compared to JPY 24,748 million a year ago. Diluted earnings per share was JPY 52.95 compared to JPY 45.41 a year ago. Total cash flows from operating activities was JPY 33,036 million compared to JPY 26,001 million a year ago. Purchase of property, plant and equipment was JPY 9,207 million compared to JPY 6,476 million a year ago. Purchase of intangible assets was JPY 1,267 million compared to JPY 425 million a year ago. Core revenues were JPY 222 billion compared to JPY 201 billion a year ago. Core operating profit JPY 43.7 billion compared to JPY 38.7 billion a year ago. Core net income JPY 29.8 billion compared to JPY 25.6 billion a year ago. The company announced dividend of JPY 22 per share for the second quarter of 2014 compared to JPY 22 per share paid in a year ago. Date on which dividend payments to commence: September 1, 2014. The company provided dividend guidance for the year end of fiscal 2014. For the end of fiscal year 2014, the company expects to pay dividend of JPY 23 per share compared to JPY 23 per share paid in a year ago. The company provided consolidated earnings guidance for the year ending December 31, 2014. For the full year, the company expects revenue of JPY 451,000 million, core operating profit of JPY 71,000 million and core loss per share of JPY 12.7 per share.

Chugai Pharmaceutical Co. Ltd. to Report Q2, 2014 Results on Jul 24, 2014

Chugai Pharmaceutical Co. Ltd. announced that they will report Q2, 2014 results on Jul 24, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed

4519 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
View Industry Companies

Industry Analysis


Industry Average

Valuation 4519 Industry Range
Price/Earnings 33.8x
Price/Sales 4.2x
Price/Book 3.2x
Price/Cash Flow 34.7x
TEV/Sales 3.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHUGAI PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at